Hematology & Oncology
Division of Hematology and Oncology
 |
Coy Heldermon, MD, PhD Assistant Professor Division of Hematology / Oncology University of Florida 1600 SW Archer Road/Box 100277 Gainesville, FL 32610-0277 (352) 273-7832/FAX (352) 273-5006 |
Coy D. Heldermon, M.D., Ph.D., is a board certified medical oncologist with expertise in the treatment of breast cancer. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases. He also studies the spread of stem cells from maternal or malignant sources using mouse models.
Training:
| Degree Program |
Institution | Field/Specialty |
| B.S. | Oklahoma State University | Animal Science |
| M.D. | University of Oklahoma | Medicine |
| Ph.D. | University of Oklahoma | Biochemistry & Molecular Biology |
| Internship | Stanford University | Obstetrics & Gynecology |
| Residency | Washington University in St. Louis | Internal Medicine |
| Fellowship | Washington University in St. Louis | Hematology & Oncology |
Clinical Interests:
Diagnosis and Treatment of Breast Cancer
Research Interests:
His primary research efforts are in two areas.
His primary focus is on developing new therapeutic strategies using gene therapy and stem cell therapy for patients with inherited diseases such as lysosomal storage disorders and hemophilias. He is focused on studying the frequent cell transfer between mother and fetus during gestation that establish microchimerism and is determining ways to modulate the level of this chimerism to enable therapy of disease. Through the use of gene replacement, he hopes to correct the underlying deficiencies underpinning the disease manifestations.
Additionally he is studying the spread of breast malignancies through the use of xenografting. By studying the spread of tumors from breast cancer patients in mice, he hopes to determine if metastases is determined by tumor specific or host factors. This model will allow identification of what factors are important in tumor spread and localization. Additionally, the model will allow testing of therapeutic agents. The goal is to identify new targets for therapy to personalize oncologic therapeutics.
Representative Publications:
- Heldermon, C., Hennig, A, Ohlemiller, K., Ogilvie, J., Herzog, E., Breidenbach, A., Vogler, C., Wozniak, D.F., Sands, M. S. Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS ONE 2007 Aug 22;8:e772.
- Heldermon, C., Ellis, M. (2006) Endocrine Therapy for Breast Cancer. Update on Cancer Therapeutics. 1 (3):285-297
- Heldermon, C., Ohlemiller, K., Herzog, E., Vogler, C., Wozniak, D.F., Sands, M. S. Comparative therapeutic efficacy of bone marrow transplant, intracranialAAV-mediated gene therapy or both in the mouse model of MPS IIIB. (manuscript in preparation)
- Heldermon, C., DeAngelis, P.L., and Weigel, P.H. (2000) Topological Organization of the Hyaluronan Synthase from Streptococcus pyogenes, J. Biol. Chem. 276, 2037-2046
- Heldermon, C., Tlapak-Simmons, V. L., Baggenstoss B.A., and Weigel, P. H. Site-directed mutation of conserved cysteine residues does not inactivate the Streptococcus pyogenes hyaluronan synthase. Glycobiology 2001 Dec; 11(12):1017-24.